Tamsulosin Can Improve Lower Urinary Tract Symptoms in Patients Under Active Surveillance Due to Low Risk Prostate Cancer: Prospective Controlled Study
Journal Title: Üroonkoloji Bülteni - Year 2019, Vol 18, Issue 3
Abstract
Objective: We aimed to evaluate the efficacy of tamsulosin in the treatment of lower urinary tract symptoms (LUTS) in patients under active surveillance (AS) for low-risk prostate cancer (Pca). Materials and Methods: Patients who underwent prostate biopsy between 2010 and 2014 were evaluated prospectively. Inclusion criteria for AS were PSA level below 10 ng/mL, a tumor in a maximum of two cores, a tumor core percentage below 50%, a clinical stage ≤ T2a and a Gleason score ≤6. Patients under AS with LUTS were included in the study group and patients with benign pathology results with LUTS were included in the control group. International prostate symptom score (IPSS) and uroflowmetry test were used to evaluate LUTS. The maximum flow rate (Qmax) was recorded. All patients received tamsulosin 0.4 mg once daily in a modified-release formulation (Flomax MR®, Astellas, Japan). Transurethral resection prostatectomy (TUR-P) was performed when surgical treatment was necessary for obstruction despite tamsulosin treatment. Results: The study included a total of 91 patients, 41 patients in the AS group and 50 patients in the control group. Patients were assessed after six months. There was a 30% reduction in IPSS in the AS group and 24.5% in the control group (p=0.591). Qmax increased by 20.4% in the AS group and by 20% in the control group (p=0.985). The need for TUR-P was similar between the two groups (14.6% vs 20%, p=0.503) during three-year follow-up. Conclusion: Tamsulosin can be used safely and with high efficacy for LUTS in patients under AS for low-risk Pca. The improvement in IPSS and Qmax, and the need for surgical treatment were similar to the control group.
Authors and Affiliations
Ayhan Dalkılıç, Göksel Bayar, Muhammet Fatih Kılınç, Abdulmecit Yavuz, Orhan Tanrıverdi, Kaya Horasanlı
Keywords
Related Articles
- EP ID EP634292
- DOI 10.4274/uob.galenos.2018.1189
- Views 57
- Downloads 0
Current Status in the Surgery and Conservative Management of Upper Urinary System Tumors
Upper urinary tract urothelial cancers constitute 5% of all urothelial cancers and standard therapy is bladder cuff excision with nephroureterectomy. This treatment is performed as open or technologically assisted (lapar...
Contemporary Trends in Adjuvant and Neoadjuvant Treatment for Renal Cell Carcinoma
Renal cell carcinoma is an increasingly significant cancer in which surgical resection is still the sole curative approach. There is a risk of recurrence in one-third of patients after surgery. Successful experiences wit...
Histopathologic Parameters Accompanying by Incidental Prostate Cancer
Objective: It is known that incidental prostate cancer (IPCa) can be seen in a low possibility for patients who were performed transurethral resection of the prostate (TURP) due to bladder outlet obstruction and/ or pro...
Information about Prostate Cancer for Urologist: Ga-68 Prostate Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Scintigraphy
Recently, prostate-specific membrane antigen (PSMA), a glutamate carboxypeptidase II enzyme, has transformed intoan excited radiopharmaceutical agent as a result of radiolabeling of small peptides that are developed for...
Which Patients Should Undergo Immediate or Deferred Cystectomy in Non-Muscle Invazive Bladder Cancer? Evaluation of Selection Criteria
Bladder cancer is the most common malignancy of the urinary tract in Europe. 70% of all muscle invasive is bladder cancer (MIBC) at the time of diagnosis whereas remaining 30% is non-muscle invasive bladder cancer (NMIBC...